Concordant with our results, a significant upregulation of PAI-1 in tissue and plasma of bladder cancer patients compared with healthy individuals has previously been reported (Becker et al, 2010).
We were not able to detect KRT7 protein in either plasma or urine from bladder cancer patients.
Plasma, urine, liver, gall bladder, muscle, and tumour samples obtained from RIF-1 tumour-bearing C3H/Hej mice were assessed for putative [F]FETA metabolites by HPLC.
We examined the relation between BK virus antibodies and cancers of the prostate, kidney and bladder, in plasma collected prior to diagnosis, in a case control study nested within the Oxford component of the European Prospective Investigation into Cancer and Nutrition (EPIC-Oxford).
Previous studies have reported elevated MMP-7 concentration in urine samples and also in plasma samples from patients with bladder cancer.
In addition, activation of PAR1 receptors with specific agonists administered systemically results in plasma extravasation in the rat bladder due to release of SP from terminal afferents [38].
Proteomic analysis has also been performed using urinary and plasma proteins from patients with bladder cancers [ 18, 19].
Four of these six patients also had other tumours (i.e. two cutaneous, one tumour of soft tissue, lung, larynx tumour or bladder, and one plasma cell tumour).
Radiochromatograms of plasma, liver, tumour, muscle, gall bladder, and urine that were obtained at 10 (plasma, liver, and tumour) and 60 min (all tissues and body fluids) after the administration of [F]FETA are shown in Figure 4.
These studies, in which no functional parameter has been assessed, show that pretreatment with a NOS inhibitor prevents increased CYP-induced extravasation, bladder weight, and plasma nitrite-nitrate levels.
